1. Home
  2. GLSI

as 05-24-2024 4:00pm EST

$
-
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Greenwich LifeSciences Inc is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. Its Product Candidates include; GP2, a HER2/neu transmembrane peptide that elicits a targeted immune response against HER2/neu-expressing cancers, GM-CSF Immunoadjuvant has been shown to enhance monocyte and neutrophil cytotoxicity against melanoma tumor cells and to enhance activity-dependent cellular cytotoxicity of monocytes and neutrophils against targets coated with the anti-ganglioside antibodies, and Cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells to inhibit the spread of cancer.

Founded: 2006 Country:
United States
United States
Employees: N/A City: STAFFORD
Market Cap: 180.0M IPO Year: 2020
Target Price: $36.00 AVG Volume (30 days): 43.2K
Analyst Decision: Strong Buy Number of Analysts: 1
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.72 EPS Growth: N/A
52 Week Low/High: $7.58 - $21.44 Next Earning Date: 05-20-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks:

Stock Insider Trading Activity of Greenwich LifeSciences Inc. (GLSI)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Patel Snehal GLSI CEO and CFO Apr 1 '24 Buy $19.08 3,000 $57,240.00 5,350,777 SEC Form 4
Patel Snehal GLSI CEO and CFO Mar 22 '24 Buy $19.98 2,500 $49,950.00 5,347,777 SEC Form 4
Patel Snehal GLSI CEO and CFO Mar 5 '24 Buy $12.49 3,500 $43,715.00 5,343,777 SEC Form 4
Patel Snehal GLSI CEO and CFO Mar 5 '24 Buy $12.49 30,500 $380,945.00 5,343,777 SEC Form 4
Patel Snehal GLSI CEO and CFO Feb 15 '24 Buy $11.07 12,700 $140,589.00 5,325,377 SEC Form 4